Autres langues Entera Bio Ltd.

Actions

ENTX

IL0011429839

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
1,98 ^USD	-1,00 %		-0,50 %	+230,00 %

08/04	Entera Bio Ltd. annonce la publication des données de l'essai de phase 2 sur les comprimés de peptide PTH(1-34) oral (EB613) dans le Journal of Bone and Mineral Research	CI
26/03	Entera Bio Ltd. annonce une étape réglementaire clé pour le programme de phase 3 du peptide oral PTH(1-34) (EB613) : La décision de la FDA sur la qualification de la DMO comme critère de substitution pour les médicaments contre l'ostéoporose est attendue dans les 10 mois.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research	08/04
Entera Bio Ltd. Announces Publication of Oral PTH(1-34) Peptide Tablets Phase 2 Trial Data in the Journal of Bone and Mineral Research	08/04
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months	26/03
Entera Bio Ltd. Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs Is Expected Within 10 Months	26/03
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	20/03
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	20/03
Entera Bio Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates	08/03
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement	04/03
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	30/01
Top Premarket Gainers	18/01
Top Premarket Gainers	17/01
Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule	03/01
Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025	26/12
Entera Bio Ltd. announced that it has received $6.610594 million in funding	22/12
Entera Bio Ltd. announced that it expects to receive $6.610594 million in funding	20/12
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform	29/11
Entera Bio Ltd. Announces Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform	29/11
Entera Bio Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development	14/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Entera Bio Ltd.

Actions

ENTX

IL0011429839

Autres langues

Filtres